| Austin Taylor Greenwood, FNP | |
|
4230 Philips Farm Rd, Columbia, MO 65201-0067 | |
| (573) 882-4800 | |
| (573) 884-0723 |
| Full Name | Austin Taylor Greenwood |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 11 Years |
| Location | 4230 Philips Farm Rd, Columbia, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134651128 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Rhea Medical Center | Dayton, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Skin Cancer And Cosmetic Dermatology Center Pc | 8224118773 | 23 |
News Archive
Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has initiated a Phase 2/3 clinical trial of its proprietary investigational drug ADS-5102 (amantadine HCl extended release) for the treatment of levodopa induced dyskinesia (LID) in patients with Parkinson's disease.
AdvanDx today announced that it will offer the BinaxNOW PBP2a test from Inverness Medical Innovations, Inc. (Waltham, MA) to customers in the United States. The test provides rapid detection of the penicillin-binding protein 2a present in Methicillin-Resistant Staphylococcus aureus (MRSA) directly from S. aureus positive blood cultures.
Columbia University Medical Center (CUMC) scientists have demonstrated that two related enzymes - phosphoinositide-3 kinase (PI3K) gamma and delta - play a key role in the development of T-cell acute lymphoblastic leukemia (T-ALL), a highly aggressive childhood leukemia that is difficult to treat.
The Nation examines how a surge in the outsourcing of clinical trials to contract research organizations (CROs) and a resulting increase in the number of trials being conducted in the developing world, where "regulations aren't as onerous, patient recruitment is easier and informed consent is less clearly defined," has led to a rise in unregulated drug trials in South America.
Elevated levels of DNA damage have for the first time been found in the cellular mitochondria and nuclei of patients with the inherited, progressive nervous system disease called Friedreich's ataxia (FRDA), says a multicenter research team led by an expert from the University of Pittsburgh Cancer Institute (UPCI).
› Verified 9 days ago
| Entity Name | Skin Cancer & Cosmetic Dermatology Center Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144419458 PECOS PAC ID: 8224118773 Enrollment ID: O20080109000552 |
News Archive
Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has initiated a Phase 2/3 clinical trial of its proprietary investigational drug ADS-5102 (amantadine HCl extended release) for the treatment of levodopa induced dyskinesia (LID) in patients with Parkinson's disease.
AdvanDx today announced that it will offer the BinaxNOW PBP2a test from Inverness Medical Innovations, Inc. (Waltham, MA) to customers in the United States. The test provides rapid detection of the penicillin-binding protein 2a present in Methicillin-Resistant Staphylococcus aureus (MRSA) directly from S. aureus positive blood cultures.
Columbia University Medical Center (CUMC) scientists have demonstrated that two related enzymes - phosphoinositide-3 kinase (PI3K) gamma and delta - play a key role in the development of T-cell acute lymphoblastic leukemia (T-ALL), a highly aggressive childhood leukemia that is difficult to treat.
The Nation examines how a surge in the outsourcing of clinical trials to contract research organizations (CROs) and a resulting increase in the number of trials being conducted in the developing world, where "regulations aren't as onerous, patient recruitment is easier and informed consent is less clearly defined," has led to a rise in unregulated drug trials in South America.
Elevated levels of DNA damage have for the first time been found in the cellular mitochondria and nuclei of patients with the inherited, progressive nervous system disease called Friedreich's ataxia (FRDA), says a multicenter research team led by an expert from the University of Pittsburgh Cancer Institute (UPCI).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Austin Taylor Greenwood, FNP 2358 Lifestyle Way, Suite 212, Chattanooga, TN 37421-2291 Ph: (423) 521-1100 | Austin Taylor Greenwood, FNP 4230 Philips Farm Rd, Columbia, MO 65201-0067 Ph: (573) 882-4800 |
News Archive
Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has initiated a Phase 2/3 clinical trial of its proprietary investigational drug ADS-5102 (amantadine HCl extended release) for the treatment of levodopa induced dyskinesia (LID) in patients with Parkinson's disease.
AdvanDx today announced that it will offer the BinaxNOW PBP2a test from Inverness Medical Innovations, Inc. (Waltham, MA) to customers in the United States. The test provides rapid detection of the penicillin-binding protein 2a present in Methicillin-Resistant Staphylococcus aureus (MRSA) directly from S. aureus positive blood cultures.
Columbia University Medical Center (CUMC) scientists have demonstrated that two related enzymes - phosphoinositide-3 kinase (PI3K) gamma and delta - play a key role in the development of T-cell acute lymphoblastic leukemia (T-ALL), a highly aggressive childhood leukemia that is difficult to treat.
The Nation examines how a surge in the outsourcing of clinical trials to contract research organizations (CROs) and a resulting increase in the number of trials being conducted in the developing world, where "regulations aren't as onerous, patient recruitment is easier and informed consent is less clearly defined," has led to a rise in unregulated drug trials in South America.
Elevated levels of DNA damage have for the first time been found in the cellular mitochondria and nuclei of patients with the inherited, progressive nervous system disease called Friedreich's ataxia (FRDA), says a multicenter research team led by an expert from the University of Pittsburgh Cancer Institute (UPCI).
› Verified 9 days ago